VERSAMET ROYALTIES CORP
VMET · NASDAQ
Updated at 2026-10-14 08:42:09
- Today's High
- $8.75
- Today’s Low
- $8.33
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $8.73
- Previous Close
- $8.68
- Volume
- 86.88K
- Market Cap
- $1.35B
- P/E Ratio
- 264.04X
- EPS
- $0.05
Previous Day Range
52-Week Range
Company Overview
- Sector
- BASIC MATERIALS
- Industry
- Metals & Mining
- Sub-industry
- OTHER PRECIOUS METALS & MINING
- Headquarters
- 733 SEYMOUR STREET, VANCOUVER, BC, CANADA, V6B 0S6
- Country
- CA
- Listing Date
- 2025-05-20
- Fiscal Year End
- December
- Shares Outstanding
- 108.83M
- CIK
- --
- Website
- versamet.com
Viamet Pharmaceuticals Corp (VMET) is an innovative biopharmaceutical company dedicated to the development of advanced therapeutics targeting serious diseases, particularly in the areas of fungal infections and oncology, utilizing its proprietary metalloenzyme-based technology platform. With a robust and diversified clinical pipeline supported by strategic partnerships and a comprehensive intellectual property portfolio, Viamet is strategically positioned for significant growth. The company remains focused on addressing critical unmet medical needs and is committed to enhancing shareholder value through continued therapeutic advancements in its specialized areas.
Financial Metrics
Revenue
2026-06-30
$23.13M
2026-03-31
$23.63M
2025-12-31
$18.36M
2025-09-30
$8.11M
Operating Expenses
2026-06-30
$3.01M
2026-03-31
$3.54M
2025-12-31
$3.44M
2025-09-30
$1.49M
Net Income
2026-06-30
$4.77M
2026-03-31
$13.56M
2025-12-31
$15.05M
2025-09-30
$3.31M
Net Profit Margin
2026-06-30
20.63%
2026-03-31
57.39%
2025-12-31
82%
2025-09-30
40.88%
Earnings Per Share
2026-06-30
$0.04
2026-03-31
$0.28
2025-12-31
$0.41
2025-09-30
$0.13
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
$14.65M
2026-03-31
$14.23M
2025-12-31
$28.72M
2025-09-30
$7.7M
Effective Tax Rate
2026-06-30
30.02%
2026-03-31
29.54%
2025-12-31
29.77%
2025-09-30
30.39%
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $23.13M | $23.63M | $18.36M | $8.11M |
| Operating Expenses | $3.01M | $3.54M | $3.44M | $1.49M |
| Net Income | $4.77M | $13.56M | $15.05M | $3.31M |
| Net Profit Margin | 20.63% | 57.39% | 82% | 40.88% |
| Earnings Per Share | $0.04 | $0.28 | $0.41 | $0.13 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | $14.65M | $14.23M | $28.72M | $7.7M |
| Effective Tax Rate | 30.02% | 29.54% | 29.77% | 30.39% |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.